Phase-3 clinical study for a generic version of GSK's Advair Diskus is complete- Cipla

▴ Phase 3 clinical study for a generic version of GSK s Advair Diskus is complete Cipla
The study completed in the first attempt was conducted over a period of 15 months at over 100 sites enrolling 1,400 asthma patients.

Cipla announced that the phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder(100/50 mcg) has been completed.
Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg, 500/50 mcg are generic versions of GSK's Advair Diskus. The product is to be used to treat asthma in patients aged four years and above. In the long term, it will be used to treat chronic obstructive pulmonary disease(COPD), including chronic bronchitis emphysema or both for better breathing and fewer flare-ups.
The phase-3 study was conducted over a period of 15 months at over 100 sites in the US on 1,400 asthma patients. The results showed that the product is therapeutically equivalent to Advair Diskus. Also, there were no safety concerns identified during the trials.
Umang Vohra, MD and Global CEO, Cipla, said, “I am pleased with the successful completion of the phase-three clinical study of generic Advair Diskus. Considering the complexity of clinical endpoint study in the Fluticasone + Salmeterol combination, it is heartening to see that our study was successful in the first attempt. This is an important milestone and is a testament to Cipla’s strong respiratory capabilities, and will go a long way in strengthening our respiratory franchise in the US. Unmatched presence across the care continuum and the widest range of drug-device combinations have established Cipla’s position as a lung leader in India and other key emerging markets. Our endeavor is to extend this expertise across developed markets through niche product development.”

Tags : #Advaitdiskus #Cipla #Clinicaltrial #GSK #UmnagVohra #Asthmapatients

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026